Olema Pharmaceuticals Inc’s filing revealed that its 10% Owner Bain Capital Life Sciences Inv acquired Company’s shares for reported $1.73 million on Jan 08 ’25. In the deal valued at $5.76 per share,300,000 shares were bought. As a result of this transaction, Bain Capital Life Sciences Inv now holds 7,800,000 shares worth roughly $ 39.31 million.
Then, Graham G. Walmsley sold 700,761 shares, generating $4,730,137 in total proceeds. Upon selling the shares at $6.75, the Director now owns 0 shares.
Before that, Logos Opportunities Fund I LP bought 700,761 shares. Olema Pharmaceuticals Inc shares valued at $4,730,137 were divested by the Affiliate at a price of $6.75 per share.
Goldman initiated its Olema Pharmaceuticals Inc [OLMA] rating to a Buy in a research note published on April 02, 2024; the price target was $24. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in late January with a ‘”a Buy”‘ rating. Oppenheimer began covering OLMA with “an Outperform” recommendation on July 21, 2023. CapitalOne started covering the stock on May 05, 2023. It rated OLMA as “an Overweight”.
Price Performance Review of OLMA
On Tuesday, Olema Pharmaceuticals Inc [NASDAQ:OLMA] saw its stock jump 1.41% to $5.04. Over the last five days, the stock has lost -2.33%. Olema Pharmaceuticals Inc shares have fallen nearly -13.55% since the year began. Nevertheless, the stocks have fallen -66.51% over the past one year. While a 52-week high of $16.62 was reached on 02/05/25, a 52-week low of $4.60 was recorded on 01/13/25. SMA at 50 days reached $6.25, while 200 days put it at $10.41.
Levels Of Support And Resistance For OLMA Stock
The 24-hour chart illustrates a support level at 4.91, which if violated will result in even more drops to 4.79. On the upside, there is a resistance level at 5.25. A further resistance level may holdings at 5.47. The Relative Strength Index (RSI) on the 14-day chart is 39.01, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.73, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.03%. Stochastics %K at 11.56% indicates the stock is a buying.
The most recent change occurred on February 22, 2023 when Credit Suisse began covering the stock and recommended ‘”an Outperform”‘ rating along with a $12 price target.
